Literature DB >> 1777425

Skewed B cell VH family repertoire in Bcl-2-Ig transgenic mice.

T M Yeh1, S J Korsmeyer, J M Teale.   

Abstract

The proto-oncogene Bcl-2 is normally expressed in B lineage cells in a stage specific manner and extends cell survival. Deregulated Bcl-2 expression has been shown to cause a major expansion in surface IgM and IgD positive B cells. In this report, the influence of deregulated expression of Bcl-2 on the VH repertoire of B cells was studied. This was accomplished by stimulating B cells from both adult and fetal Bcl-2-Ig transgenic mice and their normal littermates using the polyclonal activator lipopolysaccharide. Activated cells were then analyzed by in situ hybridization using radiolabeled C mu and VH gene probes. The D-proximal VH families 7183 and Q52 were preferentially expressed in the adult transgenic mice compared to their normal littermates. VH 7183 and Q52 were also over-represented in fetal transgenic mice but not to a greater extent than that observed with normal fetuses. These results demonstrate that the overproduction of Bcl-2, which prolongs cell survival independent of affecting proliferation, substantially alters the VH gene repertoire.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777425     DOI: 10.1093/intimm/3.12.1329

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  2 in total

1.  Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2.

Authors:  H M Ogmundsdóttir; S Sveinsdóttir; A Sigfússon; I Skaftadóttir; J G Jónasson; B A Agnarsson
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells.

Authors:  Christian T Mayer; Jan P Nieke; Anna Gazumyan; Melissa Cipolla; Qiao Wang; Thiago Y Oliveira; Victor Ramos; Sébastien Monette; Quan-Zhen Li; M Eric Gershwin; Hamid Kashkar; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-22       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.